Novo Nordisk's Phase 3 STEP Young trial demonstrated that weekly semaglutide, combined with lifestyle changes, helped many children aged 6 to under 12 reduce their body mass index below the clinical obesity threshold. Despite this success, the stock price has not risen significantly, reflecting market hesitation due to concerns over long-term safety, pediatric treatment challenges, and payer coverage. The drug is not yet approved for children under 12, and adoption is expected to be gradual, starting with adolescents before younger children. The pediatric market represents a long-term growth opportunity for Novo Nordisk, but significant regulatory and societal hurdles remain.
Novo Nordisk shares are trading at USD 42.73, down 1.66% as of Sep 15, 2026, 23:31 WIB on Pluang. Despite the promising results from the STEP Young trial for pediatric obesity treatment, the stock price reflects some market caution. The company holds a substantial market cap of $192.10 billion, indicating strong investor interest amid ongoing regulatory and adoption challenges.
Crude oil prices surged above $100 per barrel after drone attacks forced Saudi Arabia to shut its critical East-West pipeline, which carries about 4 million barrels per day to the Red Sea port of Yanbu. This pipeline outage threatens up to 4% of the ...
Morgan Stanley downgraded Novo Nordisk to "Underweight" with a price target of $40, implying a 9.11% downside from its recent price of $44.01. The downgrade reflects concerns over a projected 21.57% drop in earnings per share to $0.80 and a 2.35% rev...
